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Abstract
Virus-specific immune responses have a major impact 
on the outcome of the infection. Viral agents that are 
characterized by latency, such as herpesviruses and 
polyomaviruses, require a continuous immune control 
to reduce the extent of viral reactivation, as viral clear-
ance cannot be accomplished, independently from the 
anti-viral treatment. In transplant patients, morbidity 
and mortality related to viral infections are significantly 
increased. In fact, the key steps of activation of T-cells 
are major target for anti-rejection immunosuppressive 
therapy and anti-viral immune response may be altered 
when infected cells and cellular effectors of immune 
response coexist in a transplanted organ. The role of 
cellular immune response in controlling viral replica-
tion and the main methods employed for its evalua-
tion will be discussed. In particular, the main features, 
including both advantages and limitations, of available 
assays, including intracellular cytokine staining, major 
histocompatibility complex - multimer-based assays, 
Elispot assay, and QuantiFERON test, will be described. 
The potential applications of these assays in the trans-
plant context will be discussed, particularly in relation 
to cytomegalovirus and polyomavirus BK infection. The 
relevance of introducing viro-immunological monitoring, 
beside virological monitoring, in order to identify the 
risk profile for viral infections in the transplant patients 
will allows for define a patient-tailored clinical manage-
ment, particular in terms of modulation of immunosup-
pressive therapy and anti-viral administration. 
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Virus-specific immune responses have a major impact on 
the outcome of  the infection. Viral infections are usually 
followed by the complete clearance of  the virus. How-
ever, in some cases, immune response is not able to elimi-
nate completely the virus, thus the infection may become 
persistent. In general, cellular immune response plays a 
more relevant role in the viral clearance, whereas humoral 
immune response protects against the reinfection. Im-
mune response may vary according to genetic substrate 
of  the individual and the degree of  immunocompetence. 
In transplant patients, morbidity and mortality related 
to viral infections are significantly increased. In fact, anti-
rejection immunosuppressive therapy weakens the im-
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mune functions and anti-viral immune response may be 
altered when infected cells and cellular effectors of  im-
mune response coexist in a transplanted organ. 
In particular, viral agents that are characterized by 
latency, such as herpesviruses and polyomaviruses, re-
quire a continuous immune control to reduce the extent 
of  viral reactivation, as viral clearance cannot be ac-
complished, independently from the anti-viral treatment. 
The immunologic control of  these viruses in the immu-
nocompromised host is complex and involves both the 
innate and adaptative immune systems. As regards innate 
immune system, polymorphisms of  Toll-like receptors as 
well as certain proteins, including complement proteins, 
and defects in natural killer cells are associated with an 
increased risk of  viral reactivation. Adaptative immune 
responses of  B and T cells are critical in controlling viral 
replication. In particular, while B cells may be important 
in the humoral response in that they produce neutralizing 
antibodies targeting virions, T-cell mediated responses, 
including both CD4+ and CD8+ T-cells, are crucial 
components for controlling viral replication of  persistent 
viruses[1]. Several phenotypic markers and functions have 
been investigated in order to characterize virus-specific 
CD4+ and CD8+ T cell responses, evidencing a great 
heterogeneity against different viruses, with functional 
signatures being probably specific for each virus and be-
ing predominantly regulated by the levels of  antigen load. 
In this context, polyfunctional secretion and proliferation 
[i.e., interferon (IFN)-γ and interleukin-2] of  CD4+ and 
CD8+ T cells play a protective role in terms of  antiviral 
immunity in chronic viral infections[2,3].
METHODS FOR EVALUATING VIRUS-
SPECIFIC CELLULAR IMMUNE RESPONSE
Evaluation of  virus-specific T-cell responses can be made 
by different methods (Table 1), including: intracellular cy-
tokine staining (ICS), major histocompatibility complex 
(MHC)-multimer-based assay, Enzyme-linked Immunospot 
(ELISPOT) assay and QuantiFERON-cytomegalovirus 
(CMV) assay (specific for CMV)[4-6]. Beside these virus-
specific assays, it is also available a non-specific test, the Im-
munKnow assay, that is used to evaluate the overall CD4+ 
immune response. 
Most of  these assays have been used in experimental 
settings and only for some of  them commercial kit are 
available. The majority of  the assays are based on the de-
tection of  IFN-γ after stimulation with specific viral anti-
gens or viral lysates, the so-called IFN-γ releasing assays 
(IGRA). Anyway, other markers, including different cyto-
kines (e.g., interleukin-2, tumor necrosis factor-α, etc.) can 
be used. In terms of  clinical utility, an ideal test should 
evaluate both virus-specific CD4+ and CD8+ T-cell im-
mune response from both quantitative (number of  virus-
specific T cells) and function (number of  functional T 
cells) points of  view. Moreover, for an appropriate use in 
the clinical setting, an assay should be easy and rapid to 
perform, relatively inexpensive, highly reproducible, and 
applicable in different routine contexts. At the moment, 
all the assays present specific advantages and limitations. 
Intracellular cytokine staining
Most studies have analyzed virus-specific T-cell responses 
using ICS for IFN-γ using flow cytometry[4]. Moreover, 
ICS allows for evaluation of  polyfunctionality of  T 
cells[2,3]. Whole blood or isolated peripheral blood mono-
nuclear cells (PBMCs) are stimulated with virus-specific 
peptides or viral lysates. The assay is not restricted for 
human leukocyte antigen (HLA) when viral lysate is used 
and there Is no need to know HLA type. Stimulated cells 
are stained with monoclonal antibodies directed against 
IFN-γ. The method is rapid, with a short incubation time 
and results being available within 24 h; can be performed 
starting from low blood volume (approximately 1 mL); 
it allows for identification of  CD4+ and CD8+ T cells. 
The major drawbacks are the need for a flow cytometer 
and the lack of  standardization. Among the advantages, 
there is the possibility to freeze the cells and send them 
to reference laboratory for testing.
MHC - multimer-based assays
MHC-multimer-based assays is characterized by the di-
rect staining of  peptide-specific T-cells using peptide-
conjugated MHC class Ⅰ tetramers or pentamers[7]. This 
method evaluates CD8+ T-cell responses, however it is 
epitope-specific and require knowledge of  the patient’
s HLA type. As for ICS, there is the need for access to a 
flow cytometer and the assay is not standardized. Among 
the advantages, the assay is rapid (1-2 h) and can be per-
formed starting from low blood volume (0.5-1 mL). 
Elispot
The ELISPOT assay determines the number of  T-cells 
secreting IFN-γ in specific response to a viral agent. Fol-
lowing stimulation with viral peptides or viral lysates, the 
produced IFN-γ is captured by a specific antibody, and 
then quantified using a labeled antibody[8]. The assay evalu-
ates both CD4+ and CD8+ responses and there is no 
need to know HLA, as well as to use a flow cytometer. 
There is the possibility to freeze the cells and send them to 
reference laboratory for testing. Among the diasadvantag-
es, the method requires a relatively high volume of  blood 
(approximately 7-10 mL) and cannot differentiate between 
CD4+ and CD8+ cells. Although some approaches to 
standardize the assay, it is still not standardized. Results 
are available within 24-30 h. A mitogen control assay can 
determine general T-cell responsiveness. Commercially 
available kits for virus-specific ELISPOT assays are avail-
able (AID, Autoimmun Diagnostika GmbH, Strassberg, 
Germany).
QuantiFERON-CMV
This is a CMV-specific ELISA-based IFN-γ release assay 
and is commercially available (Cellestis Inc., Melbourne, 
Australia). It can be easily performed starting from low 
blood volume (3 mL) and results are available after 
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30-40 h. It evaluates only CD8+ responses. The assay 
may yield nonresponse results in the presence of  global 
immunosuppression (nonresponse to mitogen) as in 
transplant patients. Test sensitivity decreases in lympho-
penic patients because an appropriate number of  T-cells 
are required for the production of  IFN-γ.
ImmunKnow assay
The Cylex ImmunKnow assay (Cylex Inc., Columbia, 
MD, US) is a aspecific assay, which is commercially 
available. It measures the overall immune response and 
is indicative of  immunesuppression. It determines the 
amount of  ATP produced in response to whole-blood 
stimulation by an aspecific mitogen (phytohemagglutinin). 
ROLE OF VIRUS-SPECIFIC CELLULAR 
IMMUNE RESPONSE IN TRANSPLANT 
PATIENTS
T-cell responses, including both CD4+ and CD8+, are 
critically important for controlling viral replication. This 
has been demonstrated by the use of  adoptive immuno-
therapy for treatment of  CMV and EBV infections and 
by the higher frequency of  viral reactivation in patients 
treated with anti-lymphocyte agents. Early reconstitution 
of  cellular immune response prevents or reduces the du-
ration of  the infection, thus avoiding the onset of  disease 
or relapses. On the other hand, a delayed or reduced 
response represents the pathogenic base for the occur-
rence of  repeated episode of  infection and symptomatic 
disease (in the absence of  anti-viral treatment)[7-11]. The 
role of  cellular immune response in the context of  organ 
transplantation has been studied particularly for CMV. 
In particular, it has been evidenced the basic role played 
by both CD4+ and CD8+ responses[9]. The CD8+ re-
sponse is prevalent during the acute phase of  infection 
and it provides for an immediate control of  viral replica-
tion by the killing of  cells in which CMV is replicating. 
The CD4+ response is fundamental for the long-term 
maintenance of  antiviral control. In a study on solid-
organ transplant recipients, it has been demonstrated that 
stable levels of  CMV-specific CD4+ cells correlates with 
the absence of  infectious complications, whereas in pa-
tients with unstable levels of  specific-CD4+ cells, several 
episodes of  viral reactivation occurred[10]. The median 
frequency of  CMV-specific CD8+ cells was significantly 
higher in a group of  27 heart and lung transplant patients 
in cases that did not developed CMV-disease[11]. More-
over, in a study on 73 renal transplant recipients, also the 
median frequency of  CMV-specific CD4+ cells was sig-
nificantly higher in patients that did not developed CMV 
disease[12,13]. Gerna and coll. proposed the classification 
of  transplant recipients into two groups in relation to 
the temporal profile for CMV-specific cellular immune 
response[14]. The Authors considered a group of  early 
responders, in which reconstitution of  cellular immune 
response occurred within 30 d posttransplantation, and 
a group of  late responders, in which cellular immune re-
sponse reconstitution occurred at > 30 d posttransplanta-
tion and/or was reduced. In these patients, the delay in 
CD4+ response appeared to be particularly critical[15]. 
Another virus for which specific cellular response 
has been investigated is polyomavirus BK. It has been 
evidenced that healthy BKV-seropositive individuals 
have CD4+ and CD8+ cells specific for BKV major an-
tigens (including large T antigen and capsid viral protein 
VP1)[16]. The unbalance between viral replication and 
BKV-specific cellular immune response should repre-
sent the common denominator for the pathogenesis of  
polyomavirus-associated nephropathy, a viral-associated 
complication potentially leading to the lost of  the trans-
planted organ and mainly occurring in renal transplant 
patients[15,16]. It has been evidenced that cellular response 
to large T antigen and VP1 is significantly higher in pa-
tients with decreasing viremia in comparison to those with 
increasing viremia[16]. Moreover, it seems that the level of  
immune response is correlated particularly to the adminis-
tration of  some immunosuppressive drugs. For example, 
in a study on kidney transplant patients in vivo, responses 
were inversely correlated with tacrolimus through levels, 
but not mycophenolate mofetil, prednisone or the over-
all immunosuppressive dosing[17]. However, the clinical 
role of  BKV viro-immunological monitoring in renal 
transplant recipient needs to be further investigated, in 
particular it is likely that it could represent an approach to 
modulate immunosuppression.
An interesting issue in the context of  protective im-
munity is represented by the role of  mucosal immuniza-
tion. As mucosal surfaces represent the major entry fro 
many human pathogens (including HSV, HIV, respiratory 
viruses, as well as mycobacteria), induction of  mucosal 
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Table 1  Methods for evaluating cellular immune response
Method Advantages Limitations
Intracellular cytokine staining Low volume blood Flow cytometer required
Rapid Not standardized
Knowledge of HLA not required
Identification of CD4+ and CD8+
MHC multimer staining Low volume blood Flow cytometer required
Rapid Not standardized
Elispot assay Identification of CD4+ and CD8+ Not standardized
MHC: Major histocompatibility complex; HLA: Human leukocyte antigen.
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immune system, including both innate and adaptative 
responses (CD4+ T helper cells, Th17 cells, high avidity 
CD8+ cytotoxic T lymphocytes, as well as IgA and IgG1 
neutralizing antibodies) seem required for an effective 
protection against pathogens that lead to chronic infec-
tions[18,19]. 
CONCLUSION
The increase in the number of  transplant patients and 
the use of  deeply immunosuppressive drugs have lead to 
the emergence of  viral infections that may influence the 
outcome of  these patients. Beside the adoption of  proto-
cols for close virological monitoring, several studies have 
underlined the role of  viro-immunological monitoring in 
the evaluation of  patient’s risk of  infection and disease, 
decision on treatment by modulating immunosuppression 
and/or using antiviral, and adoption of  other diagnostic 
strategies. There is no defined method to evaluate the cel-
lular immune response in transplant recipients, as at the 
moment no assay is standardized and further studies, par-
ticularly on procedures, quality controls and references, as 
well as interpretation of  results are required to standard-
ize. However, ELISPOT assay is gaining increasing rec-
ognition due to the potential to evaluate both CD4+ and 
CD8+ responses and other favoring features. Further 
studies on the clinical role of  cellular immune responses 
are required, in particular with the aim of  define modes 
and temporal profile for viro-immunological monitor-
ing in different transplant contexts and for different viral 
agents.
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